Skip to main content
MTVA
NASDAQ Life Sciences

MetaVia's Obesity Drug DA-1726 Accepted for Late-Breaking Poster at EASL Congress

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.11
Mkt Cap
$5.549M
52W Low
$1
52W High
$19.029
52W Position info
11% above low
Off High info
94% below high
Rel. Volume info
2.6× avg
Market data snapshot near publication time

MTVA is trading near its 52-week low of $1 (11% above the low) on elevated volume (2.6× avg).

Summary

MetaVia announced that a late-breaking abstract for its obesity drug candidate, DA-1726, has been accepted for a poster presentation at the upcoming European Association for the Study of the Liver (EASL) Congress, providing further visibility for the asset.


Key Events · Product Development and Regulatory · MTVA

  • Abstract Accepted for Major Conference

    A late-breaking abstract highlighting DA-1726, MetaVia's novel dual GLP-1/glucagon analog for obesity, has been accepted for a poster presentation at the European Association for the Study of the Liver (EASL) Congress 2026.

  • Presentation Scheduled

    The poster presentation is scheduled for May 27-30, 2026, in Barcelona, Spain, with MetaVia's Chief Medical Officer, Chris Fang, listed as the presenting author.

  • Ongoing Clinical Development

    DA-1726 is currently being evaluated in a 16-week Phase 1 Part 3 titration study, with data from this study anticipated in the fourth quarter of 2026.


Analysis · MTVA · Life Sciences

For a clinical-stage biotechnology company like MetaVia, the acceptance of a late-breaking abstract for a key pipeline asset at a major medical conference like EASL is an important positive development. It increases the visibility and scientific validation of DA-1726, their dual GLP-1/glucagon analog for obesity. This news provides a positive clinical update amidst the company's ongoing financial challenges, including a going concern warning and a proposed reverse stock split, potentially boosting investor sentiment by highlighting pipeline progress.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MTVA was trading at $1.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $1.00 to $19.03. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MTVA - Latest Insights

MTVA
Nov 13, 2026, 8:36 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.40
Real-time Price: $1.30 info
Change: -$0.100 (-7%) info
Market Cap: $8.565M info
MTVA
Nov 13, 2026, 8:35 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.40
Real-time Price: $1.30 info
Change: -$0.100 (-7%) info
Market Cap: $8.565M info
MTVA
Nov 13, 2026, 8:31 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.40
Real-time Price: $1.30 info
Change: -$0.100 (-7%) info
Market Cap: $8.565M info
MTVA
Nov 12, 2026, 8:41 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.51
Real-time Price: $1.30 info
Change: -$0.210 (-14%) info
Market Cap: $8.565M info
MTVA
Nov 05, 2026, 9:15 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.32
Real-time Price: $1.30 info
Change: -$0.0193 (-1%) info
Market Cap: $8.565M info